Neuren Pharmaceuticals Limited (ASX:NEU)

Neuren Pharmaceuticals Cash Flow Statement

Financials in millions AUD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	142.04	157.08	0.18	-7.79	-9.19
Depreciation & Amortization	0.02	0.02	0.01	0.01	0.01
Loss (Gain) From Sale of Investments	-3.59	1.53	0.7	-	-
Stock-Based Compensation	1.23	2.93	1.99	0.84	0.39
Other Operating Activities	10.44	0.14	0.18	-0.4	0.72
Change in Accounts Receivable	-157.59	-13.11	0.19	-2.51	-0.2
Change in Accounts Payable	-	-	0.34	-0.11	0.19
Change in Income Taxes	-3.83	36.35	-	-	-
Operating Cash Flow	-11.27	184.93	3.6	-9.97	-8.08
Operating Cash Flow Growth	-	5038.23%	-	-	-
Capital Expenditures	-0.01	-0.04	-0.02	-0.01	-0.01
Investment in Securities	4.14	-211.45	-	-	-
Investing Cash Flow	4.13	-211.49	-0.02	-0.01	-0.01
Issuance of Common Stock	1.66	3.64	-	23.28	20.22
Repurchase of Common Stock	-10.43	-	-	-	-
Other Financing Activities	-0.01	-0.02	-0	-1.11	-1.08
Financing Cash Flow	-8.78	3.62	-0	22.18	19.14
Foreign Exchange Rate Adjustments	1.97	-0.15	-0.18	0.4	-0.71
Net Cash Flow	-13.94	-23.09	3.4	12.6	10.34
Free Cash Flow	-11.28	184.89	3.58	-9.98	-8.08
Free Cash Flow Growth	-	5064.39%	-	-	-
Free Cash Flow Margin	-5.20%	79.71%	23.22%	-312.17%	-1127.48%
Free Cash Flow Per Share	-0.09	1.41	0.03	-0.08	-0.08
Cash Income Tax Paid	37.22	-0.88	-1.39	-2.52	-0.49
Levered Free Cash Flow	-42.25	152.97	2.59	-6.76	-5.12
Unlevered Free Cash Flow	-42.25	152.97	2.59	-6.76	-5.12
Change in Net Working Capital	155.47	-25.53	-1.07	2.46	0.01

Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.